PTC Therapeutics to Host Deep Dive Webinar on Splicing Platform

News provided by

Jul 21, 2020, 09:00 ET

SOUTH PLAINFIELD, N.J., July 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET.

The splicing platform deep dive will provide an overview of PTC's validated splicing platform which leverages its cutting-edge technology to selectively and specifically identify molecules that modulate mRNA splicing to upregulate or downregulate protein production. The deep dive will review the mechanisms underlying the splicing platform obtained over 10 years of development that have driven the platform's progress to date and yielded PTC's discovery of risdiplam. PTC will also provide a clear roadmap for the vast potential of the splicing platform moving forward.

The webinar can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the webinar and providing the passcode 9153632. A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. A webcast replay will be available approximately two hours after completion of the webinar and will be archived for 30 days following the webinar.

About the Splicing Platform
PTC uses its alternative splicing technology to identify molecules that modulate mRNA splicing. Approximately 94% of all human genes undergo splicing. Through alternative splicing, by including or excluding exons, one gene can generate several mRNA products that can have different biological functions. PTC has developed a powerful high-throughput drug discovery technology that enables us to identify small molecule modifiers of pre-mRNA splicing. Using this technology, we have successfully identified oral small molecules to upregulate splicing of a key protein for spinal muscular atrophy. Based on the knowledge and experience from the SMA program, we believe that other small molecule drug candidates can be identified that modify alternative splicing of genes, promote inclusion of specific exons into mRNA or force skipping of undesired exons from the mature mRNA. We believe that this technology has a broad potential applicability to a large number of target genes in all therapeutic areas.

About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:

Investors:
Alex Kane
+1 (908) 912-9643

Media:
Jane Baj
+1 (908) 912-9167
[email protected]

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

SOURCE PTC Therapeutics, Inc.